Latest news
Revolution Medicines (RVMD) BeOne Deal Puts Its Valuation Back In Focus - simplywall.stsimplywall.st · Tue, 11 Aug 2026 03:39:58 GMTONC (ONC) insiders schedule $83.9M ADS sale under Rule 144 - Stock TitanStock Titan · Mon, 10 Aug 2026 20:37:30 GMTBeOne and Revolution Medicines partner on RAS(ON) inhibitor combinations in Asia - AllSciAllSci · Mon, 10 Aug 2026 16:11:22 GMTRevMed, BeOne make clinical trial, Asia deal; MoonLake reports Phase 3 win - Endpoints NewsEndpoints News · Mon, 10 Aug 2026 15:33:00 GMTBOCOM International Holdings Company Keeps Their Buy Rating on BeOne Medicines Ltd (6160) - The Globe and MailThe Globe and Mail · Mon, 10 Aug 2026 14:44:00 GMTBeOne Medicines (ONC) Is Up 11.0% After Raising 2026 Revenue and Operating Income Guidance – What's Changed - simplywall.stsimplywall.st · Mon, 10 Aug 2026 13:39:53 GMTBeOne Medicines and Revolution Medicines Partner on RAS(ON) Cancer Therapies - OncodailyOncodaily · Mon, 10 Aug 2026 13:21:02 GMTRevolution Medicines, BeOne Medicines form collaboration on RAS cancer drug combinations - BitgetBitget · Mon, 10 Aug 2026 12:17:21 GMT